logo-loader
viewHelix BioPharma Corp.

Full interview: Helix BioPharma closes financing as they look to uplist to Nasdaq exchange

Helix BioPharma (TSE: HBP) CEO Dr Heman Chao sat down with Steve Darling from Proactive in New York to share details they have just completed a fundraise. Chao also talked about his desire to uplist the company to the Nasdaq. 

Dr Chao also told Proactive what is planned this year in the development of their L-DOS47 cancer drug. 

Quick facts: Helix BioPharma Corp.

Price: 1.35 CAD

TSX:HBP
Market: TSX
Market Cap: $172.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: NexTech AR Resources signs new deal for augmented reality in...

NexTech AR Solutions (CSE:NTAR-OTCQB: NEXCF) CEO Evan Gappelberg joined Steve Darling from Proactive Vancouver with news the company has signed another deal with a company in the arms sector. This deal is with Steyr Arms, a world-renowned firearms manufacturer.  Gappelberg says NexTech...

58 minutes ago

2 min read